<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048151</url>
  </required_header>
  <id_info>
    <org_study_id>GV-001.012</org_study_id>
    <nct_id>NCT01048151</nct_id>
  </id_info>
  <brief_title>TNFerade Biologic to Treat Locally Advanced Prostate Cancer</brief_title>
  <official_title>A PHASE I SAFETY AND TOLERABILITY TRIAL OF RADIOTHERAPY, ANDROGEN DEPRIVATION, AND INTRATUMORAL INJECTIONS OF AdGVEGR.TNF.11D (TNFeradeTM) FOR PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GenVec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>GenVec</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      While radiation therapy with androgen ablation (hormone reduction) is the standard method of&#xD;
      treating locally advanced prostate cancer. New treatments are being combined with radiation&#xD;
      therapy in an effort to further improve the cure rates.&#xD;
&#xD;
      This study proposes to combine an experimental drug, TNFerade™ Biologic, (also called&#xD;
      AdGVEGR.TNF.11D or &quot;TNFerade&quot;) at different dose (amounts) levels in combination with&#xD;
      radiation.&#xD;
&#xD;
      TNFerade™ Biologic is a form of gene transfer therapy that when injected into the tumor has&#xD;
      shown to increase the effect of radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Locally Advanced Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Single</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TNFerade™ Biologic + Radiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TNFerade™ Biologic</intervention_name>
    <description>AdGVEGR.TNF.11D</description>
    <arm_group_label>Single</arm_group_label>
    <other_name>TNFerade™</other_name>
    <other_name>AdGVEGR.TNF.11D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Histological documented high-risk localized prostate cancer defined by clinical stage&#xD;
             &gt;=T3 or Gleason score ≥8.&#xD;
&#xD;
          -  Lack of distant metastases (including bone, liver, or extrapelvic lymph node&#xD;
             metastases) on standard CT and bone scanning. Patients with suspected or&#xD;
             histologically confirmed pelvic lymph node metastases are eligible.&#xD;
&#xD;
          -  Normal organ function defined by:&#xD;
&#xD;
               -  Hgb &gt; 10 mg/dl (may be transfused or on erythropoietin);&#xD;
&#xD;
               -  Platelets &gt; 100,000/l;&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 1500/l.&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 mg/dl.&#xD;
&#xD;
          -  AST and ALT &lt; 1.5X upper limit of normal.&#xD;
&#xD;
          -  Written signed informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Absolute or relative contraindication to prostate radiotherapy including but not&#xD;
             limited to prior pelvic radiotherapy, active infectious or inflammatory colitis, and&#xD;
             inability to lay supine for daily radiation treatments.&#xD;
&#xD;
          -  Requirement for ongoing antithrombotic treatment with coumadin or one of its&#xD;
             derivatives, heparin or one of its derivatives, or thrombin inhibitors. Low dose&#xD;
             aspirin for prevention of cardiovascular events is acceptable.&#xD;
&#xD;
          -  Active vascular disease defined as a stroke, transient ischemic attack (TIA),&#xD;
             myocardial infarction, or any vascular procedure performed for ischemic disease within&#xD;
             the last 6 months.&#xD;
&#xD;
          -  History of thrombosis (pulmonary embolism (PE) or deep vein thrombosis (DVT)) or known&#xD;
             thrombophilia.&#xD;
&#xD;
          -  Coagulopathy (INR&gt;1.5, PTT ratio &gt;1.5)&#xD;
&#xD;
          -  Major surgery within the last 1 month (excludes minor superficial surgeries, biopsies,&#xD;
             or minimally invasive approaches).&#xD;
&#xD;
          -  Chemotherapy or experimental medications within 4 weeks of study entry.&#xD;
&#xD;
          -  Chronic treatment for greater than 6 months with oral steroids at doses above 10&#xD;
             mg/day prednisolone (or equivalent).&#xD;
&#xD;
          -  Clinical evidence of active infection of any type.&#xD;
&#xD;
          -  HIV-positive patients receiving combination anti-retroviral therapy.&#xD;
&#xD;
          -  Other significant concurrent medical or psychiatric illness that would limit&#xD;
             compliance with study.&#xD;
&#xD;
          -  Unwilling to use condoms or another barrier method of birth control for at least 8&#xD;
             weeks following the last dose of TNFerade™ Biologic and some form of birth control for&#xD;
             at least one year. -&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Beth Manchen</last_name>
    <phone>773-702-4135</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2010</study_first_posted>
  <last_update_submitted>March 8, 2012</last_update_submitted>
  <last_update_submitted_qc>March 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2012</last_update_posted>
  <responsible_party>
    <name_title>Paul Fischer, PhD, CEO</name_title>
    <organization>GenVec</organization>
  </responsible_party>
  <keyword>Prostate</keyword>
  <keyword>TNFerade Biologic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

